Announcements Trials
Browse Landscape

Phase

Phase 2 26Phase 1 15Phase NA 10Phase 1/2 5Phase 3 4Phase 4 1

Status

Completed 34Terminated 11Active not recruiting 7Unknown 4Recruiting 4

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Myeloid 4

Conditions

Breast Neoplasms 129Carcinoma, Non-Small-Cell Lung 101Prostatic Neoplasms 62Colorectal Neoplasms 49Nasopharyngeal Carcinoma 46Neoplasms 43Multiple Myeloma 41Stomach Neoplasms 34Lung Neoplasms 32Ovarian Neoplasms 31Neoplasm Metastasis 31Leukemia, Myeloid, Acute 31Carcinoma, Hepatocellular 29Squamous Cell Carcinoma of Head and Neck 27Rectal Neoplasms 27Triple Negative Breast Neoplasms 25Recurrence 25Pancreatic Neoplasms 25Small Cell Lung Carcinoma 21Esophageal Neoplasms 21Brain Neoplasms 21Uterine Cervical Neoplasms 20Colonic Neoplasms 20Lymphoma, Large B-Cell, Diffuse 18Head and Neck Neoplasms 17Urinary Bladder Neoplasms 16Leukemia, Lymphocytic, Chronic, B-Cell 16Esophageal Squamous Cell Carcinoma 16Carcinoma, Renal Cell 16Myasthenia Gravis 15

Interventions

luspatercept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Recruiting × Myeloproliferative Disorders × Clear all
NCT04064060 2025-11-12

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Celgene

Phase 3 Recruiting
665 enrolled
Myeloid

Myelodysplastic Syndromes, Myeloproliferative Disorders, beta-Thalassemia

NCT06468033 2025-08-13

P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk

PharmaEssentia

Phase 3 Recruiting
150 enrolled
Myeloid

Myeloproliferative Disorders, Primary Myelofibrosis

NCT06740916 2024-12-27

Long-term Efficacy of Once Daily Versus Twice Daily Aspirin in High-risk MPN Patients With Aspirin Resistance

Siriraj Hospital

Phase 3 Recruiting
240 enrolled
Myeloid

Myeloproliferative Disorders

NCT04655092 2024-11-08

Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients

PharmaEssentia Japan K.K.

Phase 3 Recruiting
67 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera

Data powered by HemOnc (CC BY 4.0) Colophon âš¡